Velesco Pharma triples capacity with Michigan facility acquisition

New plant will replace and consolidate the company’s existing clinical manufacturing site in Kalamazoo, MI

Velesco Pharma is set to triple its clinical manufacturing capacity with the purchase and fit-out of a new, state-of-the-art facility in Wixom, Michigan.

The new building will feature expanded processing suite space to provide enhanced cGMP clinical trial material capabilities to the pharmaceutical development and clinical manufacturing company. This facility will be supported by Michigan-based Velesco Pharma's existing QC release and stability testing laboratory also located in Wixom. It will replace and consolidate the company’s existing manufacturing site in Kalamazoo, MI.

As part of the expansion, the company has continued to invest in its growing team with the recent promotion of two senior leaders. Peter Angus has moved into the role of Vice President of Research while Lisa Crandall is now Vice President of Development. Both have been with Velesco Pharma since its inception.

Founded in 2007, Velesco Pharma supports early and later-stage drug development through contract analytical and drug formulation services, along with cGMP clinical supplies offering a full range of non-sterile dosage forms.

Dave Barnes, Velesco Pharma's CEO, said: "This investment in new space and increase in our capacity will enable us to meet growing client demands for cGMP clinical manufacturing services while still maintaining our science-focus and flexible approach to client projects."

The new facility is set to be fully operational by the end of this year.